13,360 Shares in NeoGenomics, Inc. (NASDAQ:NEO) Purchased by Strategic Financial Concepts LLC

Strategic Financial Concepts LLC acquired a new stake in NeoGenomics, Inc. (NASDAQ:NEO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 13,360 shares of the medical research company’s stock, valued at approximately $220,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in shares of NeoGenomics in the 3rd quarter valued at about $312,000. Inspire Investing LLC grew its stake in NeoGenomics by 12.0% in the 3rd quarter. Inspire Investing LLC now owns 28,094 shares of the medical research company’s stock worth $414,000 after acquiring an additional 3,006 shares during the period. Creative Planning increased its stake in NeoGenomics by 42.3% in the third quarter. Creative Planning now owns 23,547 shares of the medical research company’s stock valued at $347,000 after purchasing an additional 7,004 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of NeoGenomics by 42.3% during the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after acquiring an additional 987 shares during the period. Finally, Nisa Investment Advisors LLC raised its stake in NeoGenomics by 5.0% during the third quarter. Nisa Investment Advisors LLC now owns 45,104 shares of the medical research company’s stock worth $665,000 after purchasing an additional 2,166 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on NEO. Jefferies Financial Group assumed coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They set a “buy” rating and a $22.00 price target for the company. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a report on Friday, January 10th. Benchmark downgraded NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. The Goldman Sachs Group decreased their price target on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Finally, Bank of America upped their price target on shares of NeoGenomics from $18.00 to $19.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, NeoGenomics has an average rating of “Moderate Buy” and a consensus target price of $20.20.

Insider Activity at NeoGenomics

In other news, General Counsel Alicia C. Olivo sold 5,175 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the completion of the transaction, the general counsel now owns 37,129 shares of the company’s stock, valued at approximately $570,301.44. The trade was a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 1.30% of the company’s stock.

NeoGenomics Stock Up 2.2 %

Shares of NASDAQ:NEO opened at $13.78 on Thursday. The company’s fifty day moving average is $15.91 and its two-hundred day moving average is $15.64. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. NeoGenomics, Inc. has a 1-year low of $12.13 and a 1-year high of $19.11. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -22.59 and a beta of 1.23.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.